Interactions
| ID | Title | drug 1 Sort descending | drug 1 dose | drug 1 effect | drug 2 | drug 2 dose | drug 2 effect | Clinical Effects | Color | Clinical Bottom Line | Management | Alt Agents | Info Source | Edit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6864 | Lenacapavir Everolimus | Lenacapavir | Everolimus | Potential increased risk of immunosuppressant adverse effects |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Initiate adjusted dose of immunosuppressant to account for increased concentration and follow up with therapeutic drug monitoring to refine dosing. Monitor for adverse effects of immunosuppressant. Consult with specialist as necessary. |
Sunlenca Product Label | ||||||
| 6880 | Lenacapavir Methadone | Lenacapavir | Methadone | Unknown effect on methadone |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If initiating methadone in a person already on lenacapavir, start with lowest feasible dose and titrate to clinical effect. If initiating lenacapavir in a person stable on methadone, dose adjustment of methadone may be required. Monitor for clinical efficacy and adverse effects (e.g. sedation, respiratory depression). |
Sunlenca Product Label | ||||||
| 6896 | Lenacapavir Prednisone | Lenacapavir | Prednisone | Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression). |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If co-administering, initiate with the lowest starting dose and titrate to clinical effect. Monitor for corticosteroid-related adverse effects (e.g. Cushing's syndrome, adrenal insufficiency). |
DHHS Adult ARV Guidelines | ||||||
| 6912 | Lenacapavir Tacrolimus | Lenacapavir | Tacrolimus | Potential increased risk of immunosuppressant adverse effects |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Initiate adjusted dose of immunosuppressant to account for increased concentration and follow up with therapeutic drug monitoring to refine dosing. Monitor for adverse effects of immunosuppressant. Consult with specialist as necessary. |
Sunlenca Product Label | ||||||
| 6833 | Lenacapavir Bedaquiline | Lenacapavir | Bedaquiline | Potential for increased bedaquiline levels |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Consider alternative agents. If coadministering, monitor LFTs and ECG. |
DHHS Adult ARV Guidelines | ||||||
| 6849 | Lenacapavir Dexamethasone | Lenacapavir | Dexamethasone | Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression). |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If co-administering, initiate with the lowest starting dose and titrate to clinical effect. Do not use doses of dexamethasone > 16 mg. Monitor for dexamethasone-related adverse effects. |
DHHS Adult ARV Guidelines | ||||||
| 6865 | Lenacapavir Famotidine | Lenacapavir | 300 mg orally x 1 | AUC increased 28% |
Famotidine | 40 mg daily | Not reported |
No clinically significant effect expected |
Green: Administer standard doses | Administer standard doses | DHHS Adult ARV Guidelines | |||
| 6881 | Lenacapavir Methylergonovine | Lenacapavir | Methylergonovine | Increased risk of methylergonovine adverse effects |
Red: Avoid combination | Do not coadminister: potentially increased levels of methylergonovine | Use alternative agents |
DHHS Adult ARV Guidelines | ||||||
| 6897 | Lenacapavir Primidone | Lenacapavir | Primidone | Potential loss of antiviral efficacy |
Red: Avoid combination | Do not coadminister: reduced levels of lenacapavir | Use alternative agents. |
DHHS Adult ARV Guidelines | ||||||
| 6913 | Lenacapavir Tadalafil | Lenacapavir | Tadalafil | Increased risk of tadalafil adverse effects (e.g. flushing, headache, hypotension) |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Pulmonary arterial hypertension: coadministration of lenacapavir with tadalafil is not recommended. Erectile dysfunction: When used on an "as needed" basis, tadalafil dose should not exceed 10 mg every 72 hours. If used once daily (chronic administration), tadalafil dose should not exceed 2.5 mg daily. |
Sunlenca Product Label | ||||||
| 6931 | Rilpivirine (IM) Ketoconazole | Rilpivirine (IM) | Ketoconazole | Potential for increased rilpivirine concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, use standard doses and consider monitoring for antifungal efficacy and QTc prolongation |
|||||||
| 6947 | Rilpivirine (IM) Phenobarbital | Rilpivirine (IM) | Phenobarbital | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6932 | Rilpivirine (IM) Atorvastatin | Rilpivirine (IM) | Atorvastatin | Green: Administer standard doses | Administer standard doses | |||||||||
| 6948 | Rilpivirine (IM) Phenytoin | Rilpivirine (IM) | Phenytoin | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6933 | Rilpivirine (IM) DTG | Rilpivirine (IM) | Dolutegravir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6949 | Rilpivirine (IM) Dexamethasone | Rilpivirine (IM) | Dexamethasone | Decreased rilpivirine effects if dexamethasone is given as more than a single-dose treatment |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents if therapy requires more than a single dose treatment of dexamethasone. |
|||||||
| 6934 | Rilpivirine (IM) Ethinyl estradiol / Norethindrone acetate | Rilpivirine (IM) | Ethinyl estradiol / Norethindrone acetate | Green: Administer standard doses | Administer standard doses | |||||||||
| 6950 | Rilpivirine (IM) Azithromycin | Rilpivirine (IM) | Azithromycin | Potential for increased rilpivirine concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Consider alternative agents. If coadministration is necessary, monitor for adverse effects |
|||||||
| 6935 | Rilpivirine (IM) Sildenafil | Rilpivirine (IM) | Sildenafil | Green: Administer standard doses | Administer standard doses | |||||||||
| 6951 | Rilpivirine (IM) Clarithromycin | Rilpivirine (IM) | Clarithromycin | Potential for increased rilpivirine concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Consider alternative agents. If coadministration is necessary, monitor for adverse effects |
|||||||
| 6936 | Rilpivirine (IM) Chlorzoxazone | Rilpivirine (IM) | Chlorzoxazone | Green: Administer standard doses | Administer standard doses | |||||||||
| 6952 | Rilpivirine (IM) Erythromycin | Rilpivirine (IM) | Erythromycin | Potential for increased rilpivirine concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Consider alternative agents. If coadministration is necessary, monitor for adverse effects |
|||||||
| 6937 | Rilpivirine (IM) SOF | Rilpivirine (IM) | Sofosbuvir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6953 | Rilpivirine (IM) Acetaminophen | Rilpivirine (IM) | Acetaminophen | Green: Administer standard doses | Administer standard doses | |||||||||
| 6938 | Rilpivirine (IM) Famotidine | Rilpivirine (IM) | Famotidine | Green: Administer standard doses | Administer standard doses | |||||||||
| 6954 | Rilpivirine (IM) Darunavir/ritonavir | Rilpivirine (IM) | Darunavir, Ritonavir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6939 | Rilpivirine (IM) SOF/VEL | Rilpivirine (IM) | Sofosbuvir / Velpatasvir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6955 | Rilpivirine (IM) Raltegravir | Rilpivirine (IM) | Raltegravir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6940 | Rilpivirine (IM) CBZ | Rilpivirine (IM) | Carbamazepine | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6956 | Rilpivirine (IM) Tenofovir disoproxil fumarate | Rilpivirine (IM) | Tenofovir Disoproxil Fumarate | Green: Administer standard doses | Administer standard doses | |||||||||
| 6941 | Rilpivirine (IM) Oxcarbazepine | Rilpivirine (IM) | Oxcarbazepine | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6957 | Rilpivirine (IM) Digoxin | Rilpivirine (IM) | Digoxin | Green: Administer standard doses | Administer standard doses | |||||||||
| 6942 | Rilpivirine (IM) St. John's Wort (Hypericum perforatum) | Rilpivirine (IM) | St. John's Wort | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6958 | Rilpivirine (IM) Metformin | Rilpivirine (IM) | Metformin | Green: Administer standard doses | Administer standard doses | |||||||||
| 6943 | Rilpivirine (IM) RPT | Rilpivirine (IM) | Rifapentine | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6944 | Rilpivirine (IM) Omeprazole | Rilpivirine (IM) | Omeprazole | Green: Administer standard doses | Administer standard doses | |||||||||
| 6929 | Rilpivirine (IM) Methadone | Rilpivirine (IM) | Methadone | Potential for reduced methadone concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, monitor for methadone efficacy |
|||||||
| 6945 | Rilpivirine (IM) RIF | Rilpivirine (IM) | Rifampin | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6930 | Rilpivirine (IM) Aluminum and magnesium hydroxide antacid | Rilpivirine (IM) | Aluminum and magnesium hydroxide antacid | Green: Administer standard doses | Administer standard doses | |||||||||
| 6946 | Rilpivirine (IM) RFB | Rilpivirine (IM) | Rifabutin | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
